Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat

Journal of Toxicology

Volumn 2017, Issue , 2017, Pages

  Rasmussen, Caroline E ^a   Nowak, Jette ^a   Larsen, Julie M ^a   Moore, Emma ^b   Bell, David ^b   Liu, Kai Chiu ^b   Sorensen, Nanna Skall ^a   Kappers, Wendela A ^a   Krogh Meibom, Thomas ^a   Offenberg, Hanne ^a  

^a NOVO NORDISK A S   (Denmark)

^b Department of Bioanalytical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; MACROGOL DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHRONIC TOXICITY; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD INTAKE; HEMOPHILIA A; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OPHTHALMOSCOPY; PATHOLOGY; PHYSICAL EXAMINATION; RAT; TOXICOKINETICS; TREATMENT DURATION;

EID: 85018630975     PISSN: 16878191     EISSN: 16878205     Source Type: Journal    
DOI: 10.1155/2017/8496246     Document Type: Article

References (25)

1. J. Mahlangu, J. S. Powell, M. V. Ragni et al., "Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A," Blood, vol. 123, no. 3, pp. 317-325, 2014.
2. R. Webster, V. Elliottt, B. Kevin Park, D. Walker, M. Hankin, and P. Taupin, "PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals," in PEGylated Protein Drugs: Basic Science and Clinical Applications, Milestones in Drug Therapy, pp. 127-146, Birkhäuser, Basel, Switzerland, 2009.
3. D. G. Rudmann, J. T. Alston, J. C. Hanson, and S. Heidel, "High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins," Toxicologic Pathology, vol. 41, no. 7, pp. 970-983, 2013.
4. European Medicines Agency, "EMEA 664021 EPAR Cimzia," August 2015, European Medicines Agency website: http://www .ema.europa.eu/docs/en-GB/document-library/EPAR---Public assessment-report/human/001037/WC500069735.pdf.
5. I. A. Ivens, W. Achanzar, A. Baumann et al., "PEGylated biopharmaceuticals: current experience and considerations for nonclinical development," Toxicologic Pathology, vol. 43, no. 7, pp. 959-983, 2015.
6. A. Bendele, J. Seely, C. Richey, G. Sennello, and G. Shopp, "Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins," Toxicological Sciences, vol. 42, no. 2, pp. 152-157, 1998.
7. R. Webster, E. Didier, P. Harris et al., "PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies," Drug Metabolism and Disposition, vol. 35, no. 1, pp. 9-16, 2007.
8. International Conference on Harmonisation, ICH Harmonised Tripartite Guideline. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6 (R1), International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2011, http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S6-R1/Step4/S6-R1-Guideline.pdf.
9. International Conference on Harmonisation, ICH Harmonised Tripartite Guideline. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6 (R1), International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2011, http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S6-R1/Step4/S6-R1-Guideline.pdf.
10. P. Lollar, "Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX," Journal of Thrombosis and Haemostasis, vol. 2, no. 7, pp. 1082-1095, 2004.
11. K. Øvlisen, A. T. Kristensen, and M. Tranholm, "In vivo models of haemophilia-status on current knowledge of clinical phenotypes and therapeutic interventions," Haemophilia, vol. 14, no. 2, pp. 248-259, 2008.
12. K. R. Sørensen, K. Roepstorff, B. Wiinberg et al., "The F8(/) rat as a model of hemophilic arthropathy," Journal ofThrombosis and Haemostasis, vol. 14, no. 6, pp. 1216-1225, 2016.
13. M. Cugno, R. Gualtierotti, A. Tedeschi, and P. L. Meroni, "Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy," Autoimmunity Reviews, vol. 13, no. 1, pp. 40-48, 2014.
14. M. A. Hanes, "The nude rat," in The Laboratory Rat, M. A. Suckkow, S. H.Weisbroth, and C. L. Franklin, Eds., pp. 733-759, Elsevier, Burlinton, Mass, USA, 2006.
15. H.-J. Schuurman, "The nude rat," Human & Experimental Toxicology, vol. 14, no. 1, pp. 122-125, 1995.
16. Center for Drug Evaluation and Research, "NDA 202799 Pharmacology review(s). Omontys (peginesatide)," August 2015, US Food and Drug Administration website: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2012/202799Orig1s000PharmR .pdf.
17. European Medicines Agency, EMEA 647257 CHMP Safety Working Party's Response to the PDCO Regarding the Use of PEGylatedDrug Products in the Paediatric Population, European Medicines Agency, 2012, http://www.ema.europa.eu/docs/en GB/document-library/Scientific-guideline/2012/11/WC500135123 .pdf.
18. H. R. Stennicke, M.Kjalke,D. M.Karpf et al., "Anovel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models," Blood, vol. 121, no. 11, pp. 2108-2116, 2013.
19. L. Thim, B. Vandahl, J. Karlsson et al., "Purification and characterization of a new recombinant factor VIII (N8)," Haemophilia, vol. 16, no. 2, pp. 349-359, 2010.
20. J. R. Latendresse, A. R. Warbrittion, H. Jonassen, and D. M. Creasy, "Fixation of testes and eyes using a modified Davidson's fluid: comparison with Bouin's fluid and conventional Davidson's fluid," Toxicologic Pathology, vol. 30, no. 4, pp. 524-533, 2002.
21. C. E. Rasmussen, J. Nowak, J. M. Larsen, A. Bottomley, A. Rowles, and H. Offenberg, "Evaluation of nonacog beta pegol long-term safety in the immune-deficient rowett nude rat (Crl:NIH-Foxn1rnu)," Toxicologic Pathology, vol. 44, no. 5, pp. 726-737, 2016.
22. N.A.Andreollo, E. F.D. Santos, M. R. Aráujo, and L. R. Lopes, "Rat's age versus human's age: what is the relationship" Arquivos Brasileiros De Cirurgia Digestiva, vol. 25, no. 1, pp. 49-51, 2012.
23. I. A. Ivens, A. Baumann, T. A.McDonald, T. J.Humphries, L. A. Michaels, and P.Mathew, "PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers," Haemophilia, vol. 19, no. 1, pp. 11-20, 2013.
24. R. Stidl, S. Fuchs, M. Bossard, J. Siekmann, P. L. Turecek, and M. Putz, "Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates," Haemophilia, vol. 22, no. 1, pp. 54-64, 2016.
25. U.S. Food and Drug Administration, FDA Approves Modified Antihemophilic Factor for Hemophilia A, U S Food and Drug Administration, 2016, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472643.htm.